AZD-6738

• CAT Number: I001359
• CAS Number: 1352226-88-0
• Molecular Formula: C20 H24 N6 O2 S
• Molecular Weight: 412.51
• Purity: ≥95%
• Synonyms: AZD6738; AZD-6738; 4-[4-[1-[[S(R)]-S-methylsulfonimidoyl]cyclopropyl]-6-[(3R)-3-methyl-4-morpholinyl]-2-pyrimidinyl]-1H-pyrrolo[2,3-b]pyridine
• Target: PI3K/Akt/mTOR
• Solubility: DMSO: ≥ 38 mg/mL
• Storage: -20°C
• IC50: 1 nM
• IUPAC Name: imino-methyl-[1-[6-[(3R)-3-methylmorpholin-4-yl]-2-(1H-pyrrolo[2,3-b]pyridin-4-yl)pyrimidin-4-yl]cyclopropyl]-oxo-lambda6-sulfane
• InChI: InChI=1S/C20H24N6O2S/c1-13-12-28-10-9-26(13)17-11-16(20(5-6-20)29(2,21)27)24-19(25-17)15-4-8-23-18-14(15)3-7-22-18/h3-4,7-8,11,13,21H,5-6,9-10,12H2,1-2H3,(H,22,23)/t13-,29-/m1/s1
• InChIKey: OHUHVTCQTUDPIJ-JYCIKRDWSA-N
• SMILES: C[C@@H]1COCCN1C2=NC(=NC(=C2)C3(CC3)[S@](=N)(=O)C)C4=C5C=CNC5=NC=C4

AZD-6738（Cat No.:I001359）is a selective inhibitor of the ataxia telangiectasia and Rad3-related protein (ATR), playing a crucial role in cancer therapy. By targeting ATR, AZD-6738 impairs DNA damage response pathways, enhancing the efficacy of DNA-damaging agents and radiotherapy in cancer cells. This compound is particularly effective against tumors with defective DNA repair mechanisms, making it a promising candidate for combination therapies in oncology. Its potential to sensitize cancer cells to treatment underlines its significance in advancing targeted cancer therapies and improving patient outcomes.